Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research.

Garetosmab (REGN 2477) specifically binds to and blocks signaling of activin proteins containing the inhibin βα subunit (activins A, AB, and AC). In vitro, Garetosmab has high affinity and specificity for activins A, AB, and AC, but does not bind or functionally inhibit other TGF-β family ligands that share the same activin receptor pathways, including activin B, inhibin A, BMP-2, BMP6, BMP9, BMP10, GDF8, and GDF11.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Frédéric Vanhoutte, et al. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431.  [Content Brief]